Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.4% during the 4th quarter, HoldingsChannel reports. The fund owned 3,833 shares of the biopharmaceutical company’s stock after acquiring an additional 265 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Alnylam Pharmaceuticals were worth $902,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Eventide Asset Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after buying an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Telemark Asset Management LLC acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $27,503,000. Geode Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after acquiring an additional 66,928 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ALNY shares. Sanford C. Bernstein lowered their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $278.99 on Wednesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a market capitalization of $35.98 billion, a price-to-earnings ratio of -106.48 and a beta of 0.34. The business has a 50 day moving average price of $248.91 and a two-hundred day moving average price of $260.56. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.15 earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold a total of 21,372 shares of company stock valued at $5,634,205 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.